SG10201808867PA - Anti-nme antibody - Google Patents

Anti-nme antibody

Info

Publication number
SG10201808867PA
SG10201808867PA SG10201808867PA SG10201808867PA SG10201808867PA SG 10201808867P A SG10201808867P A SG 10201808867PA SG 10201808867P A SG10201808867P A SG 10201808867PA SG 10201808867P A SG10201808867P A SG 10201808867PA SG 10201808867P A SG10201808867P A SG 10201808867PA
Authority
SG
Singapore
Prior art keywords
antibody
nme
nme7
bind
family
Prior art date
Application number
SG10201808867PA
Other languages
English (en)
Inventor
Cynthia Bamdad
Benoit Smagghe
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/050773 external-priority patent/WO2015023694A2/en
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of SG10201808867PA publication Critical patent/SG10201808867PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
SG10201808867PA 2014-04-07 2015-04-07 Anti-nme antibody SG10201808867PA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461976390P 2014-04-07 2014-04-07
PCT/US2014/050773 WO2015023694A2 (en) 2013-08-12 2014-08-12 Method for enhancing tumor growth
USPCT/US2014/061821 2014-10-22
US201562114526P 2015-02-10 2015-02-10
US201562127746P 2015-03-03 2015-03-03

Publications (1)

Publication Number Publication Date
SG10201808867PA true SG10201808867PA (en) 2018-11-29

Family

ID=54288530

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201808867PA SG10201808867PA (en) 2014-04-07 2015-04-07 Anti-nme antibody
SG11201608389RA SG11201608389RA (en) 2014-04-07 2015-04-07 Anti-nme antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201608389RA SG11201608389RA (en) 2014-04-07 2015-04-07 Anti-nme antibody

Country Status (11)

Country Link
US (4) US20170204196A1 (ja)
EP (2) EP4050103A1 (ja)
JP (5) JP6401292B2 (ja)
KR (2) KR102294483B1 (ja)
CN (1) CN106414726A (ja)
AU (1) AU2015243948B2 (ja)
CA (1) CA2945162A1 (ja)
IL (2) IL248220A0 (ja)
SG (2) SG10201808867PA (ja)
TW (1) TWI746420B (ja)
WO (1) WO2015157322A2 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2945162A1 (en) 2014-04-07 2015-10-15 Minerva Biotechnologies Corporation Use of an anti-nme antibody for treatment or prevention of cancer
US11746159B2 (en) 2015-02-10 2023-09-05 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
CA3039797A1 (en) * 2016-10-11 2018-04-19 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
US20210087143A1 (en) * 2017-03-29 2021-03-25 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
CA3128384A1 (en) * 2019-02-04 2020-08-13 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
WO2021252551A2 (en) * 2020-06-08 2021-12-16 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
AU2021297535A1 (en) * 2020-06-26 2023-02-16 Minerva Biotechnologies Corporation Anti-NME antibody and method of treating cancer or cancer metastasis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874285A (en) * 1996-09-13 1999-02-23 Incyte Pharmaceuticals, Inc. Polynucleotide encoding a novel human nm23-like protein
AU7721500A (en) 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US7202346B2 (en) * 2002-07-03 2007-04-10 Immunogen Inc. Antibodies to non-shed Muc1 and Muc16, and uses thereof
WO2004050860A2 (en) * 2002-12-04 2004-06-17 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
KR20190122749A (ko) * 2009-06-11 2019-10-30 미네르바 바이오테크놀로지 코포레이션 줄기세포 및 전구세포를 배양하는 방법
CN107699585A (zh) * 2010-12-09 2018-02-16 宾夕法尼亚大学董事会 嵌合抗原受体‑修饰的t细胞治疗癌症的用途
AU2012326137B2 (en) * 2011-10-17 2018-11-29 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
US20140010861A1 (en) * 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
CA2880010A1 (en) * 2012-07-24 2014-01-30 Minerva Biotechnologies Corporation Nme variant species expression and suppression
JP6664219B2 (ja) * 2012-08-14 2020-03-13 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞増強治療法
US20160326263A1 (en) 2013-02-20 2016-11-10 Minerva Biotechnologies Corporation NME Inhibitors and Methods of Using NME Inhibitors
IL240695B2 (en) * 2013-02-20 2024-03-01 Minerva Biotechnologies Corp NME inhibitors and methods of using NME inhibitors
CA2945162A1 (en) 2014-04-07 2015-10-15 Minerva Biotechnologies Corporation Use of an anti-nme antibody for treatment or prevention of cancer

Also Published As

Publication number Publication date
JP7042854B2 (ja) 2022-03-28
JP2017512825A (ja) 2017-05-25
SG11201608389RA (en) 2016-11-29
US11702483B2 (en) 2023-07-18
KR20160142372A (ko) 2016-12-12
TWI746420B (zh) 2021-11-21
WO2015157322A2 (en) 2015-10-15
US20190031778A1 (en) 2019-01-31
IL248220A0 (en) 2016-11-30
TW201542595A (zh) 2015-11-16
US20220289865A1 (en) 2022-09-15
CA2945162A1 (en) 2015-10-15
US20170204196A1 (en) 2017-07-20
EP3129476A2 (en) 2017-02-15
EP3129476A4 (en) 2017-11-08
JP6401292B2 (ja) 2018-10-10
JP2022095648A (ja) 2022-06-28
JP2020073562A (ja) 2020-05-14
KR102294483B1 (ko) 2021-08-27
EP3129476B1 (en) 2022-01-05
JP2018203765A (ja) 2018-12-27
AU2015243948B2 (en) 2020-10-15
KR20210107166A (ko) 2021-08-31
IL291164A (en) 2022-05-01
JP2024084747A (ja) 2024-06-25
US20190031779A1 (en) 2019-01-31
AU2015243948A1 (en) 2016-10-27
WO2015157322A3 (en) 2015-12-23
EP4050103A1 (en) 2022-08-31
JP6646118B2 (ja) 2020-02-14
CN106414726A (zh) 2017-02-15

Similar Documents

Publication Publication Date Title
SG10201808867PA (en) Anti-nme antibody
PH12016501644A1 (en) Binding proteins and methods of use thereof
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2019012868A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
WO2016144728A3 (en) Anti-lilrb antibodies and their use in detecting and treating cancer
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
MX2020009568A (es) Anticuerpos que se unen a cd39 y sus usos.
EP3558369A4 (en) ANTIBODIES SPECIFICALLY BINDING TO HUMAN IL-15 AND THEIR USES
EA201892294A1 (ru) Антитела и композиции против tim-3
NZ739750A (en) Anti-tigit antibodies and methods of use
EA201991214A1 (ru) Антитела против pd-1 и их композиции
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
NZ603271A (en) Anti-erbb3 antibodies
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
WO2015153997A3 (en) Notch3 antibodies and uses thereof
WO2017019957A3 (en) Binding proteins and methods of use thereof